Dynavax Technologies (DVAX) Slammed on CRL; Is it Now a Bounce Candidate?
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 7/19/2026
- Wall St ends lower for the day and week as chip selloff broadens
- Netflix earnings forecast disappoints Wall Street, shares tumble
- HSBC upgrades Apple to Buy, sees "strong cycle ahead"
- Kimi K3 AI breakthrough: What Wall Street analysts say about China’s OpenAI threat
- Why the Fed may still need to hike rates
- Assassin's Creed Black Flag Resynced sells 3M copies in a week
- Magnitude 7.4 earthquake strikes coast of Chiapas, Mexico; Tsunami waves are possible
- Magnitude 7.4 earthquake strikes Puerto Madero, Mexico, USGS says
- Medifast launches Trilivy, replacing its Optavia brand
- Adobe has received a takeover approach by a Big Tech company - Betaville
Dynavax (DVAX) Receives CRL from FDA on HEPLISAV
February 25, 2013 6:50 AM ESTDynavax Technologies Corporation (NASDAQ: DVAX) announced Monday that it received a Complete Response Letter (CRL) from the FDA regarding its Biologic License Application (BLA) for HEPLISAV, an investigational adult hepatitis B vaccine.
In the CRL, the FDA specified that the indication in adults 18-70 years of... More
Jefferies Would Still Buy Dynavax Technologies (DVAX) if CRL Issued Friday
February 21, 2013 12:20 PM ESTJefferies reiterated ts Buy rating and $5 price target on Dynavax Technologies (NASDAQ: DVAX) ahead of Friday's Heplisav FDA decision.
"We have revised our scenarios for Fridays Heplisav FDA decision and added a scenario in which the company receives a complete... More
